



Pricing Information

Adalimumab-aaty

In accordance with certain state statutes, prescription drug manufacturers are required to disclose in writing to prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the products identified below:

NDC	Product	Strength	Package Description	Package Quantity	Wholesale Acquisition Cost*	Average Wholesale Price (AWP)
72606-040-04	Adalimumab-aaty	80 mg	Auto-Injector (Pen)	1 Pen	\$519.00	\$622.80
72606-040-06	Adalimumab-aaty	80 mg	Auto-Injector (Pen)	3 Pens	\$1,557.00	\$1,868.40
72606-022-06	Adalimumab-aaty	40 mg	Prefilled Syringe with Safety Guard (PFS-S)	2 PFS-S	\$1,038.00	\$1,245.60
72606-022-09	Adalimumab-aaty	40 mg	Auto-Injector (Pen)	1 Pen	\$519.00	\$622.80
72606-022-10	Adalimumab-aaty	40 mg	Auto-Injector (Pen)	2 Pens	\$1,038.00	\$1,245.60
72606-041-01	Adalimumab-aaty	20 mg	Prefilled Syringe (PFS)	2 PFS	\$1,038.00	\$1,245.60

WAC is the manufacturer's published catalog or suggested list price for a drug product to wholesalers or distributors, as reported to third-party drug price compendia. WAC does not represent actual transaction prices or include discounts, rebates, or reductions in price. In most cases, the price paid by patients for Adalimumab-aaty will be different from the product's published WAC. How much a patient will pay for Adalimumab-aaty will depend on the patient's insurance coverage.

Certain state laws also require manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. An accepted definition of “therapeutic class” is “a group of similar drugs that have the same or similar

mechanisms of action and are used to treat a specific condition.” Adalimumab-aaty is a biosimilar drug which is a biologic medication that is highly similar to an already FDA-approved biologic product (the reference product). It has no clinically meaningful differences from the reference product in terms of safety, purity, and potency. As a biosimilar product, Adalimumab-aaty, by definition, has no generic alternative.

*Pricing as of April 22, 2025. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.



Pricing Information

STEQEYMA (ustekinumab-stba)

In accordance with certain state statutes, prescription drug manufacturers are required to disclose in writing to prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the products identified below:

NDC	Product	Strength	Package Description	Package Quantity	Wholesale Acquisition Cost*	Average Wholesale Price (AWP)
72606-027-01	STEQEYMA	45 mg	Prefilled Syringe with Safety Guard (PFS-S)	1 PFS-S	\$2,088.21	\$2,505.85
72606-028-01	STEQEYMA	90 mg	Prefilled Syringe with Safety Guard (PFS-S)	1 PFS-S	\$4,176.43	\$5,011.72
72606-029-01	STEQEYMA	130 mg	Vial	1 Vial	\$303.68	\$364.42

WAC is the manufacturer's published catalog or suggested list price for a drug product to wholesalers or distributors, as reported to third-party drug price compendia. WAC does not represent actual transaction prices or include discounts, rebates, or reductions in price. In most cases, the price paid by patients for STEQEYMA will be different from the product's published WAC. How much a patient will pay for STEQEYMA will depend on the patient's insurance coverage.

Certain state laws also require manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. An accepted definition of “therapeutic class” is “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” STEQEYMA is a biosimilar drug which is a biologic medication that is highly similar to an already FDA-approved biologic product (the reference product). It has no clinically meaningful

differences from the reference product in terms of safety, purity, and potency. As a biosimilar product, STEQEYMA, by definition, has no generic alternative.

*Pricing as of April 22, 2025. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.



Pricing Information

Vegzelma® (bevacizumab-adcd)

In accordance with certain state statutes, prescription drug manufacturers are required to disclose in writing to prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the products identified below:

NDC	Product	Strength	Package Description	Package Quantity	Wholesale Acquisition Cost*	Average Wholesale Price (AWP)
72606-011-01	Vegzelma	100 mg	Vial	1 Vial	\$677.40	\$812.88
72606-012-01	Vegzelma	400 mg	Vial	1 Vial	\$2,709.60	\$3,251.52

WAC is the manufacturer's published catalog or suggested list price for a drug product to wholesalers or distributors, as reported to third-party drug price compendia. WAC does not represent actual transaction prices or include discounts, rebates, or reductions in price. In most cases, the price paid by patients for Vegzelma will be different from the product's published WAC. How much a patient will pay for Vegzelma will depend on the patient's insurance coverage.

Certain state laws also require manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. An accepted definition of “therapeutic class” is “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” Vegzelma is a biosimilar drug which is a biologic medication that is highly similar to an already FDA-approved biologic product (the reference product). It has no clinically meaningful differences from the reference product in terms of safety, purity, and potency. As a biosimilar product, Vegzelma, by definition, has no generic alternative.

*Pricing as of April 22, 2025. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.



Pricing Information

Yuflyma® (adalimumab-aaty)

In accordance with certain state statutes, prescription drug manufacturers are required to disclose in writing to prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the products identified below:

NDC	Product	Strength	Package Description	Package Quantity	Wholesale Acquisition Cost*	Average Wholesale Price (AWP)
72606-023-04	Yuflyma	80 mg	Auto-Injector (Pen)	1 Pen	\$3,288.25	\$3,945.90
72606-023-07	Yuflyma	80 mg	Auto-Injector (Pen)	3 Pens	\$9,864.75	\$11,837.70
72606-030-06	Yuflyma	40 mg	Prefilled Syringe with Safety Guard (PFS-S)	2 PFS-S	\$6,576.50	\$7,891.80
72606-030-09	Yuflyma	40 mg	Auto-Injector (Pen)	1 Pen	\$3,288.25	\$3,945.90
72606-030-10	Yuflyma	40 mg	Auto-Injector (Pen)	2 Pens	\$6,576.50	\$7,891.80
72606-024-01	Yuflyma	20 mg	Prefilled Syringe (PFS)	2 PFS	\$6,576.50	\$7,891.80

WAC is the manufacturer's published catalog or suggested list price for a drug product to wholesalers or distributors, as reported to third-party drug price compendia. WAC does not represent actual transaction prices or include discounts, rebates, or reductions in price. In most cases, the price paid by patients for Yuflyma will be different from the product's published WAC. How much a patient will pay for Yuflyma will depend on the patient's insurance coverage.

Certain state laws also require manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. An accepted definition of “therapeutic class” is “a group of similar drugs that have the same or similar

mechanisms of action and are used to treat a specific condition.” Yuflyma is a biosimilar drug which is a biologic medication that is highly similar to an already FDA-approved biologic product (the reference product). It has no clinically meaningful differences from the reference product in terms of safety, purity, and potency. As a biosimilar product, Yuflyma, by definition, has no generic alternative.

*Pricing as of April 22, 2025. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.



Pricing Information

Zymfentra® (infliximab-dyyb)

In accordance with certain state statutes, prescription drug manufacturers are required to disclose in writing to prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the products identified below:

NDC	Product	Strength	Package Description	Package Quantity	Wholesale Acquisition Cost*	Average Wholesale Price (AWP)
72606-025-01	Zymfentra	120 mg	Auto-Injector (Pen)	1 Pen	\$3,214.16	\$3,856.99
72606-025-02	Zymfentra	120 mg	Auto-Injector (Pen)	2 Pens	\$6,428.32	\$7,713.98
72606-025-10	Zymfentra	120 mg	Prefilled Syringe with Safety Guard (PFS-S)	2 PFS-S	\$6,428.32	\$7,713.98

WAC is the manufacturer's published catalog or suggested list price for a drug product to wholesalers or distributors, as reported to third-party drug price compendia. WAC does not represent actual transaction prices or include discounts, rebates, or reductions in price. In most cases, the price paid by patients for Zymfentra will be different from the product's published WAC. How much a patient will pay for Zymfentra will depend on the patient's insurance coverage.

Certain state laws also require manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. An accepted definition of “therapeutic class” is “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” Zymfentra has no generic alternative.

*Pricing as of April 22, 2025. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.